Has FDA Reached A "New Normal"? Parexel Thinks Lower Review Metrics May Be Here To Stay, Though FDA Hopes To Improve

Shortly after the third anniversary of the FDA Amendments Act, the repercussions of FDA's new authorities and responsibilities for drug review performance are becoming clearer